Literature DB >> 8148570

Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist?

C Hassager1, S B Jensen, C Christiansen.   

Abstract

Hormone replacement therapy (HRT) prevents postmenopausal bone loss, but the prevalence of non-responders in healthy early postmenopausal women is not known. In order to study this, we reviewed data from three published studies, each carried out in a randomized, placebo-controlled, longitudinal design over 2 year, that used seven hormone replacement therapies. Bone mineral content (BMC) was measured in the distal forearm by single photon absorptiometry. A mathematical model for elimination of measurement errors was applied to published BMC data. After this correction, we found that only 1.2% of early healthy postmenopausal women who are receiving HRT in conventional doses will lose more than 1% of forearm BMC per year. In conclusion, most, if not all, healthy early postmenopausal women who might need HRT against loss of bone will respond positively in forearm BMC to such therapy.

Entities:  

Mesh:

Year:  1994        PMID: 8148570     DOI: 10.1007/bf02352259

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.

Authors:  L E Nachtigall; R H Nachtigall; R D Nachtigall; E M Beckman
Journal:  Obstet Gynecol       Date:  1979-03       Impact factor: 7.661

2.  Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy.

Authors:  B J Riis; J Jensen; C Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  1987-03       Impact factor: 3.478

Review 3.  Consensus development conference: prophylaxis and treatment of osteoporosis.

Authors: 
Journal:  Am J Med       Date:  1991-01       Impact factor: 4.965

4.  Total and local bone mineral during estrogen treatment: a placebo controlled trial.

Authors:  A Gotfredsen; B J Riis; C Christiansen
Journal:  Bone Miner       Date:  1986-04

5.  Planning a longitudinal study. II. Frequency of measurement and study duration.

Authors:  J J Schlesselman
Journal:  J Chronic Dis       Date:  1973-09

6.  Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause.

Authors:  L Nilas; C Christiansen
Journal:  Eur J Clin Invest       Date:  1988-10       Impact factor: 4.686

7.  Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss.

Authors:  L Nilas; J Borg; A Gotfredsen; C Christiansen
Journal:  J Nucl Med       Date:  1985-11       Impact factor: 10.057

8.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Authors:  R Civitelli; S Gonnelli; F Zacchei; S Bigazzi; A Vattimo; L V Avioli; C Gennari
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

9.  Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.

Authors:  C Christiansen; M S Christensen; P McNair; C Hagen; K E Stocklund; I Transbøl
Journal:  Eur J Clin Invest       Date:  1980-08       Impact factor: 4.686

10.  Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.

Authors:  J Haarbo; C Hassager; S B Jensen; B J Riis; C Christiansen
Journal:  Am J Med       Date:  1991-05       Impact factor: 4.965

View more
  7 in total

1.  Predicting the effects of estrogen replacement therapy on lumbar bone mineral density in oophorectomized women: analysis of a 10-year longitudinal study.

Authors:  Hideaki Nagata; Masahiro Nozaki; Hitoo Nakano
Journal:  Osteoporos Int       Date:  2003-10-08       Impact factor: 4.507

Review 2.  Measurement of bone mineral density.

Authors:  C Hassager; C Christiansen
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

3.  Consensus development statement on osteoporosis.

Authors:  O H Sørensen; S P Nielsen; P Charles; E F Eriksen; L Mosekilde; R P Heaney; J Falch; J Halse; E Haug
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.

Authors:  Chang Hoon Yim; Jong Tae Choi; Hyun Ah Choi; Young Soon Kang; In Gul Moon; Hyun Koo Yoon; In Kwon Han; Dae Hee Kang; Ki Ok Han
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy.

Authors:  B J Riis; K Overgaard; C Christiansen
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

Review 6.  A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.

Authors:  J P Devogelaer
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

7.  Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen.

Authors:  M Nozaki; K Koera; R Egami; H Nagata; H Nakano
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.